Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients

• DOI: 10.1007/s00280-022-04433-3
• Publication Date: 2022-04-25T10:03:56Z
• Authors: Marit A. C. Vermunt; Merel van Nuland; Lisa T. van der H...; Hilde Rosing; Jos. H. Beijnen; Andries M. Bergman
• Keywords: Male; Docetaxel; Hormones; 3. Good health; Prostatic Neoplasms, Castration-Resistant; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Tandem Mass Spectrometry; Humans; Original Article; Castration; Chromatography, Liquid; Retrospective Studies

Abstract Purpose Recently, docetaxel treatment of metastatic prostate cancer patients shifted towards the hormone-sensitive stage disease. There are contradictive reports on differences in toxicity (mHSPC) and castration-resistant (mCRPC) patients. Possible might be attributed to different pharmacokinetics (PK) two patient populations. Methods Patients with mCRPC or mHSPC a standard indication for were included study. All had suppressed serum testosterone levels (≤ 0.5 ng/mL 1.73 nmol/L). Venous blood samples obtained at first treatment, until 48 h after infusion. Plasma concentrations docetaxel, unbound metabolites measured using validated liquid chromatography coupled tandem mass spectrometry (LC–MS/MS) assays compared between groups. Moreover, transporting α1-acid glycoprotein recorded. Results A total ten nine The cohorts differed number prior treatments opiate use, which higher PK was not patients, areas under plasma concentration versus time curve (AUC 0-48 ) 1710 [coefficient variation (CV) 28.4%] 1486 (CV 25.2%) ng/mL*h ( p = 0.27), respectively. Also, profile M1/M3, M2 M4 similar both Docetaxel doses reduced 50% 11% Conclusion mCPRC Therefore, possible cannot explained by our study population. These results suggest that adaptations recommended new population mHSPC.